China Pharma Holdings (CPHI) Total Debt (2010 - 2026)

China Pharma Holdings' Total Debt history runs 17 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• Quarterly Total Debt fell 37.16% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 37.16% YoY) and the FY2025 annual result came in at $1.4 million, down 43.41% from the prior year.
• Total Debt was $1.5 million for Q1 2026 at China Pharma Holdings, up from $1.4 million in the prior quarter.
• Across five years, Total Debt topped out at $4.6 million in Q3 2022 and bottomed at $1.4 million in Q4 2025.
• A 5-year average of $2.7 million and a median of $2.5 million in 2024 frame the typical range for Total Debt.
• Peak annual rise in Total Debt reached 187.28% in 2022, while the deepest fall reached 55.69% in 2022.
• China Pharma Holdings' Total Debt stood at $2.4 million in 2022, then advanced by 4.29% to $2.5 million in 2023, then decreased by 0.38% to $2.5 million in 2024, then tumbled by 43.41% to $1.4 million in 2025, then advanced by 2.16% to $1.5 million in 2026.
• Business Quant data shows CPHI's Total Debt at $1.5 million in Q1 2026, $1.4 million in Q4 2025, and $2.0 million in Q3 2025.